October 16, 2018
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
October 9, 2018
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
July 18, 2018
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
April 24, 2018
REVOLUTION Medicines Raises $56 Million Series B Financing
October 5, 2017
REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors
September 14, 2017
Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations
March 20, 2017
REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development
December 20, 2016
REVOLUTION Medicines Raises Additional $25 Million in Series A Financing
December 13, 2016
REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles
June 14, 2016
REVOLUTION Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., and Senior Advisor, Eric Gordon, Ph.D.